Stallergenes Greer : Road show feedback: active reconstruction
>H1 lever - Note that H1 sales were up 10% and that EBITDA rose from € 8m to € 27.6m.The good performance in H1 in reality reveals a contrast between subcutaneous and sublingual, within sublingual, disparities between veterinary markets in the USA (-14%), a fall in the market share in tablets in the USA (-4pts), good capturing of new prescribing physicians in the USA (bulk / >+15%e lfl.), and sharp recovery in market share for Staloral© (increase in initial trea...Stallergenes Greer is engaged in providing a comprehensive approach to allergies diseases, offering allergy specialists a range of products from diagnosis to sublingual and subcutaneous allergen immunothreaphy medicines. Co. portfolio comprises of four product categories; Sublingual products include ORALAIR® and STALORAL®; Subcutaneous products include ALUSTAL®, PHOSTAL®, ALYOSTAL ® and ALBEY®, and GREER EXTRACTS®; Veteninary product is a range of USDA-approved bulk extracts for animals suffering from a range of allergies; and Other products offer a variety of diagnostic tools and source materials in useful formulations for allergy specialists and physicians.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.